Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Class A Ordinary Shares, par value $0.0001 per share
-
Shares outstanding
-
63.5M
-
Number of holders
-
118
-
Total 13F shares, excl. options
-
56.3M
-
Shares change
-
+542K
-
Total reported value, excl. options
-
$3.21B
-
Value change
-
+$43.1M
-
Put/Call ratio
-
13.13
-
Number of buys
-
75
-
Number of sells
-
-38
-
Price
-
$57.00
Significant Holders of MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) as of Q3 2023
142 filings reported holding MLTX - MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share as of Q3 2023.
MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) has 118 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 56.3M shares
of 63.5M outstanding shares and own 88.71% of the company stock.
Largest 10 shareholders include BVF INC/IL (21.8M shares), Cormorant Asset Management, LP (8.14M shares), FMR LLC (3.4M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.12M shares), CITADEL ADVISORS LLC (2.03M shares), Avoro Capital Advisors LLC (2M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.95M shares), T. Rowe Price Investment Management, Inc. (1.21M shares), FEDERATED HERMES, INC. (1.08M shares), and Polar Capital Holdings Plc (939K shares).
This table shows the top 118 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.